U.S. markets open in 8 hours 29 minutes
  • S&P Futures

    4,271.75
    -9.25 (-0.22%)
     
  • Dow Futures

    33,649.00
    -69.00 (-0.20%)
     
  • Nasdaq Futures

    13,545.00
    -32.75 (-0.24%)
     
  • Russell 2000 Futures

    2,011.30
    -5.60 (-0.28%)
     
  • Crude Oil

    91.20
    -0.89 (-0.97%)
     
  • Gold

    1,809.20
    -6.30 (-0.35%)
     
  • Silver

    20.61
    -0.08 (-0.40%)
     
  • EUR/USD

    1.0253
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    2.8490
    0.0000 (0.00%)
     
  • Vix

    19.53
    -0.67 (-3.32%)
     
  • GBP/USD

    1.2118
    -0.0021 (-0.17%)
     
  • USD/JPY

    133.2120
    -0.2680 (-0.20%)
     
  • BTC-USD

    24,848.78
    +286.34 (+1.17%)
     
  • CMC Crypto 200

    592.23
    +20.95 (+3.67%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,890.59
    +343.61 (+1.20%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

HHS expects over 1 mln antibody doses from Regeneron, Lilly in 2020

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Oct 9 (Reuters) - A top U.S. health official said on Friday that the government expects to have access to over 1 million doses of Regeneron Pharmaceutical Inc's and Eli Lilly's & Co's antibody treatments for COVID-19 in 2020.

The official, speaking on a call with reporters, said that the government will allocate the treatments to the states based on need, similar to the mechanism they used with Gilead Sciences Inc's antiviral drug remdesivir for COVID-19.

Both companies have said the drugs were shown to work in clinical trials and that they have submitted an emergency use authorization to the U.S. Food and Drug Administration.

The government official said the U.S. planned to distribute the treatments at no charge to patients, similar to remdesivir. (Reporting by Manas Mishra in Bengalaru and Michael Erman in New York; writing by Caroline Humer; Editing by Chizu Nomiyama)